A paclitaxel-coated balloon is superior to an uncoated balloon for the composite end point of target lesion failure among patients undergoing coronary angioplasty for in-stent restenosis, according to ...

The US Food and Drug Administration (FDA) has approved Boston Scientific's Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with ...

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI). These ...

New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...

In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and ...

TCT 1708: Kissing DCBs in NSTEMI: Sirolimus-Coated Balloon Use With Selution™ for ISR and Stent Thrombosis in a Bifurcation Lesion Receive the the latest news, research, and presentations from major ...

ABBOTT PARK, Ill., Jan. 31, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received regulatory clearance in the United States and approval in Japan for its TREK® and MINI-TREK™ ...

MIAMI LAKES, Fla., May 19, 2025 /PRNewswire/ -- Cordis, a global leader in interventional cardiovascular technologies, today announced the initiation of the SELUTION Global Coronary Registry. The ...

BUELACH, SWITZERLAND, BIOTRONIK, a leading manufacturer of cardio- and endovascular medical devices, today announced the European market launch of the Pantera Pro semi-compliant coronary balloon ...

Please provide your email address to receive an email when new articles are posted on . A drug-coated balloon produced better clinical outcomes than angioplasty at 1 year in patients with coronary ...

Paclitaxel drug-coated balloons (DCB) are not associated with increased mortality, compared with non-DCB devices, and may even confer additional survival benefits when used in coronary ...